Key Points
-
Investors were spooked by a peer’s notable reduction in sales and profitability guidance.
-
This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity.
-
10 stocks we like better than Eli Lilly ›
One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today’s trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index. That decline wasn’t necessarily Eli Lilly’s fault, though.
Reducing weight, reducing guidance
Eli Lilly’s recent popularity is due in no small measure to its plunge into the highly lucrative weight-loss drug market. In late 2023, its Zepbound — essentially the same treatment as its diabetes drug Mounjaro — was approved to treat obesity, and the company was off to the races.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
On Tuesday, though, the standard-bearer for the segment took quite a tumble. That was Novo Nordisk, which this morning lowered its guidance for both full-year sales and operating profit.
The growth forecast for the former was reduced to 8% to 14% over the 2024 tally (previous guidance range: 13% to 21%). Ditto for operating profit, which is now expected to rise in a range of 10% to 16%. That would be encouraging, if it weren’t for the fact that management’s preceding prediction was 16% to 24%.
Novo Nordisk is known for developing and selling Wegovy, the first GLP-1 drug approved by the U.S. Food and Drug Administration specifically for weight loss. The company has flown to renown and admiration on the wings of that drug, which remains a key product. Investors probably fear that Eli Lilly’s Zepbound will also perform worse than expected.
Not an emergency
I don’t think anyone should push the panic button on Eli Lilly due to this (or Novo Nordisk, while I’m at it). Demand for obesity drugs remains strong and nearly unlimited, so both Zepbound and Wegovy — which still benefit from a lack of competitors, at least for now — should continue to be growth drivers.
Also, in the case of Eli Lilly, the sprawling pharmaceutical company has a vast portfolio and a very wide development pipeline, so it’s hardly dependent on one drug — no matter how currently popular that drug might be.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $633,452!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,083,392!*
Now, it’s worth noting Stock Advisor’s total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
